LeonaBio director granted 28,000 stock options

LeonaBio, Inc. director Romano Kelly A received a grant of stock options covering 28,000 shares of common stock on April 9, 2026.

Rhea-AI Filing Summary

LeonaBio, Inc. director Romano Kelly A received a grant of stock options covering 28,000 shares of common stock on April 9, 2026. The options carry an exercise price of $9.54 per share and expire on April 8, 2036. According to the award terms, the 28,000 underlying shares are scheduled to vest in equal monthly installments over 24 months, contingent on Kelly continuing as a Service Provider under LeonaBio's 2026 Equity Incentive Plan.

Insider Trade Summary

Grant/Award: 28,000 shares

Grant/Award 1 txn

Insider Romano Kelly A

Role Director

Type	Security	Shares	Price	Value
Grant/Award	Stock Option (Right to Buy)	28,000	$0.00	$0.00

Holdings After Transaction: Stock Option (Right to Buy) — 28,000 contracts (Direct)

Footnotes (1)

1. F1. The shares subject to the option shall be scheduled to vest monthly over a term of 24 months on the monthly anniversaries of the grant date, subject to the optionee continuing to be a Service Provider (as defined in the Issuer's 2026 Equity Incentive Plan) through the applicable vesting dates.

Key Figures

Option grant size: 28,000 shares Exercise price: $9.54 per share Expiration date: April 8, 2036 +3 more

6 metrics

Option grant size 28,000 shares Stock Option (Right to Buy) granted April 9, 2026

Exercise price $9.54 per share Conversion or exercise price for granted options

Expiration date April 8, 2036 Option term end date

Underlying shares 28,000 shares Common stock underlying derivative security

Vesting period 24 months Monthly vesting on anniversaries of grant date

Shares held after transaction 28,000 options Total derivative securities following this grant

Key Terms

Stock Option (Right to Buy), 2026 Equity Incentive Plan, Service Provider, vesting

4 terms

Stock Option (Right to Buy) financial

"security_title: Stock Option (Right to Buy)"

2026 Equity Incentive Plan financial

"as defined in the Issuer's 2026 Equity Incentive Plan"

Service Provider financial

"subject to the optionee continuing to be a Service Provider"

vesting financial

"scheduled to vest monthly over a term of 24 months"

Vesting is the process by which you earn full ownership of something, like company stock or a retirement benefit, over time. It’s like earning the right to keep a gift piece by piece the longer you stay with a company, making sure employees stay committed before they receive all the benefits.

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What insider transaction did LeonaBio (LONA) report for Romano Kelly?

LeonaBio reported that director Romano Kelly A received a grant of stock options for 28,000 shares of common stock. The award is a compensation-related grant, not an open-market purchase or sale, and was reported on a Form 4 insider transaction filing.

What are the key terms of Romano Kelly’s LeonaBio stock options?

The stock options give Romano Kelly the right to buy 28,000 LeonaBio common shares at an exercise price of $9.54 per share. The options were granted on April 9, 2026 and are scheduled to expire on April 8, 2036 if not exercised.

How do Romano Kelly’s LeonaBio stock options vest over time?

The 28,000 shares underlying Romano Kelly’s stock options are scheduled to vest in equal monthly installments over 24 months. Vesting occurs on monthly anniversaries of the April 9, 2026 grant date, so long as he continues serving as a Service Provider under LeonaBio’s 2026 Equity Incentive Plan.

Did Romano Kelly buy or sell LeonaBio (LONA) shares in the market?

No open-market buying or selling occurred in this filing. Romano Kelly received a compensation-related grant of stock options with a zero-dollar grant price, giving him the right to buy shares later at $9.54, rather than immediately trading existing LeonaBio shares.

How many LeonaBio shares can Romano Kelly acquire through this option grant?

Through this grant, Romano Kelly can acquire up to 28,000 LeonaBio common shares upon exercise of the options. Actual acquisition depends on options vesting monthly over 24 months and his decision to exercise at the $9.54 per-share exercise price before the April 8, 2036 expiration.

What role does LeonaBio’s 2026 Equity Incentive Plan play in this grant?

The 2026 Equity Incentive Plan defines eligibility and service conditions for the grant. Kelly’s options vest monthly only if he continues as a qualifying Service Provider, as defined in the plan, through each applicable vesting date over the 24‑month schedule.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Form 4 Insider Transactions: What Each Field Means →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Accepted by SEC EDGAR 04/13/2026 - 04:54 PM EDT Learn about SEC filing dates

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Romano Kelly A

(Last) (First) (Middle)

C/O LEONABIO, INC.

18706 NORTH CREEK PARKWAY, SUITE 104

(Street)

BOTHELL WASHINGTON 98011

(City) (State) (Zip)

UNITED STATES

(Country)

2. Issuer Name and Ticker or Trading Symbol
LeonaBio, Inc. [ LONA ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
	Officer (give title below)		Other (specify below)

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
04/09/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Stock Option (Right to Buy)	$9.54	04/09/2026		A		28,000		(1)	04/08/2036	Common Stock	28,000	$0	28,000	D

Explanation of Responses:

1. The shares subject to the option shall be scheduled to vest monthly over a term of 24 months on the monthly anniversaries of the grant date, subject to the optionee continuing to be a Service Provider (as defined in the Issuer's 2026 Equity Incentive Plan) through the applicable vesting dates.

	/s/ Mark Worthington, Attorney in fact for Kelly A. Romano	04/13/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)